Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

441.76 -4.01 (-0.90%)

Streaming Delayed Price Updated: 10:56 AM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

74 75 Next >

Vertex to Announce First Quarter 2025 Financial Results on May 5th

April 07, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' ↗

April 07, 2025

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Via Benzinga

2 Stocks to Buy if You're Worried About a Recession ↗

April 07, 2025

Via The Motley Fool

Topics Economy Government

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm ↗

April 06, 2025

Via The Motley Fool

Topics Earnings Economy Government

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right. ↗

April 04, 2025

Via The Motley Fool

Topics Economy Energy Government

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

April 03, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...

Via StockStory

Topics Artificial Intelligence

Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗

April 02, 2025

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

Via Stocktwits

Topics ETFs Government

Is Vertex Pharmaceuticals Gaining or Losing Market Support? ↗

April 01, 2025

Via Benzinga

Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews ↗

March 31, 2025

Via Benzinga

Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data ↗

March 31, 2025

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Via Benzinga

Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). ↗

March 29, 2025

Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout.

Via Chartmill

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

March 28, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗

March 28, 2025

Via Benzinga

Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession ↗

March 28, 2025

Via The Motley Fool

Topics Economy Government Stocks

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗

March 27, 2025

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Via Investor's Business Daily

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

March 21, 2025

Via Benzinga

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

March 20, 2025

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next ↗

March 19, 2025

Via The Motley Fool

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation ↗

March 17, 2025

Via The Motley Fool

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗

March 14, 2025

Via The Motley Fool

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

March 13, 2025

Via Benzinga

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

March 13, 2025

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

Via MarketBeat

Topics Economy Supply Chain

VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) is showing promising signs of setting up for a breakout. ↗

March 12, 2025

Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout.

Via Chartmill

Top 3 Health Care Stocks That May Keep You Up At Night In Q1 ↗

March 11, 2025

Via Benzinga

Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever ↗

March 11, 2025

Via The Motley Fool

3 Reasons to Avoid VRTX and 1 Stock to Buy Instead

March 11, 2025

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.

Via StockStory

Topics Stocks

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

March 11, 2025

Via The Motley Fool

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.